Search

Your search keyword '"Felizzi, F."' showing total 47 results

Search Constraints

Start Over You searched for: Author "Felizzi, F." Remove constraint Author: "Felizzi, F."
47 results on '"Felizzi, F."'

Search Results

16. Patient-Reported Outcomes in OAK: A Phase III Study of Atezolizumab Versus Docetaxel in Advanced Non-Small-cell Lung Cancer

17. Updated Efficacy Analysis Including Secondary Population Results for OAK: A Randomized Phase III Study of Atezolizumab versus Docetaxel in Patients with Previously Treated Advanced Non–Small Cell Lung Cancer

32. Qualitative Exploration of the Visual Function Impairments and Health-Related Quality of Life Impacts of Amblyopia in Adult and Pediatric Populations.

33. Efficacy and Safety of Brolucizumab, Aflibercept, and Ranibizumab for the Treatment of Patients with Visual Impairment Due to Diabetic Macular Oedema: A Systematic Review and Network Meta-Analysis.

34. The Amblyopia Quality of Life (AmbQoL): Development and Content Validation of a Novel Health-Related Quality of Life Instrument for Use in Adult and Pediatric Amblyopia Populations.

35. A Social Media Listening Study to Understand the Unmet Needs and Quality of Life in Adult and Pediatric Amblyopia Patients.

36. Machine Learning Methods in Health Economics and Outcomes Research-The PALISADE Checklist: A Good Practices Report of an ISPOR Task Force.

37. Mixture Cure Models in Oncology: A Tutorial and Practical Guidance.

38. Cost-effectiveness of obinutuzumab versus rituximab biosimilars for previously untreated follicular lymphoma.

39. Semiparametric estimation of the cure fraction in population-based cancer survival analysis.

40. US cost-effectiveness of polatuzumab vedotin, bendamustine and rituximab in diffuse large B-cell lymphoma.

41. Cost-effectiveness of atezolizumab versus docetaxel and nivolumab in the treatment of non-small cell lung cancer as a second line in France.

42. Cost-effectiveness of second-line atezolizumab in Canada for advanced non-small cell lung cancer (NSCLC).

43. Patient-Reported Outcomes in OAK: A Phase III Study of Atezolizumab Versus Docetaxel in Advanced Non-Small-cell Lung Cancer.

44. Updated Efficacy Analysis Including Secondary Population Results for OAK: A Randomized Phase III Study of Atezolizumab versus Docetaxel in Patients with Previously Treated Advanced Non-Small Cell Lung Cancer.

45. Enhanced cellular sensitivity from partitioning the integrin receptors into multiple clusters.

46. Network-of-queues approach to B-cell-receptor affinity discrimination.

47. Analyzing and constraining signaling networks: parameter estimation for the user.

Catalog

Books, media, physical & digital resources